Literature DB >> 21594578

Non-cell-autonomous tumor suppression: oncogene-provoked apoptosis promotes tumor cell senescence via stromal crosstalk.

Maurice Reimann1, Clemens A Schmitt, Soyoung Lee.   

Abstract

Activated oncogenes evoke cellular fail-safe programs such as apoptosis, senescence, or autophagy to protect the organism from the expansion of damaged and potentially harmful cells. Non-cell-autonomous interactions between tumor cells and nonmalignant bystander cells add to cell-autonomous modes of tumor suppression during tumor development and progression. In particular, the role of stroma or host immune cells converting tumor-generated signals into a response that feeds back to the tumor cell population has been experimentally underappreciated. Using the Eμ-myc transgenic mouse lymphoma model, we elucidated how constitutive Myc signaling indirectly promotes cellular senescence via cytokines that were released by nonmalignant cells in response to oncogene-evoked cell-autonomous effects. Specifically, Myc primarily promotes apoptosis in a subset of the tumor cell population, leading to the attraction of macrophages, which subsequently engulf the apoptotic remainders. Phagocytosis-activated macrophages, in turn, exhibit strongly increased secretion of various cytokines, among them transforming growth factor beta to an extent that is capable of inducing cellular senescence in surrounding malignant cells. Our findings, recapitulated in human aggressive B-cell lymphomas, unveil that apoptosis and senescence are not simply two context-dependent cell-autonomous choices of stress responses, but rather cooperate via extracellular mediators-namely cells of the innate immune system-to profoundly limit tumorigenesis in vivo. A deeper mechanistic understanding of the organismic interconnection between different fail-safe programs will help to identify cellular components of the tumor stroma and their signal mediators that are readily available to impose a second line of host defense against cancer cells. This will open new perspectives for the development of antineoplastic therapies, whose targets not only encompass tumor but also stroma cell populations.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21594578     DOI: 10.1007/s00109-011-0770-2

Source DB:  PubMed          Journal:  J Mol Med (Berl)        ISSN: 0946-2716            Impact factor:   4.599


  54 in total

Review 1.  Unique human tumor antigens: immunobiology and use in clinical trials.

Authors:  Giorgio Parmiani; Annamaria De Filippo; Luisa Novellino; Chiara Castelli
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

Review 2.  Senescence, apoptosis and therapy--cutting the lifelines of cancer.

Authors:  Clemens A Schmitt
Journal:  Nat Rev Cancer       Date:  2003-04       Impact factor: 60.716

Review 3.  Interferons, immunity and cancer immunoediting.

Authors:  Gavin P Dunn; Catherine M Koebel; Robert D Schreiber
Journal:  Nat Rev Immunol       Date:  2006-11       Impact factor: 53.106

4.  TGF-beta directly targets cytotoxic T cell functions during tumor evasion of immune surveillance.

Authors:  Dori A Thomas; Joan Massagué
Journal:  Cancer Cell       Date:  2005-11       Impact factor: 31.743

5.  Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a.

Authors:  M Serrano; A W Lin; M E McCurrach; D Beach; S W Lowe
Journal:  Cell       Date:  1997-03-07       Impact factor: 41.582

Review 6.  The role of SHIP1 in macrophage programming and activation.

Authors:  M J Rauh; L M Sly; J Kalesnikoff; M R Hughes; L-P Cao; V Lam; G Krystal
Journal:  Biochem Soc Trans       Date:  2004-11       Impact factor: 5.407

7.  Transforming growth factor beta-induced cell cycle arrest of human hematopoietic cells requires p57KIP2 up-regulation.

Authors:  Joseph M Scandura; Piernicola Boccuni; Joan Massagué; Stephen D Nimer
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

Review 8.  Granzymes in cancer and immunity.

Authors:  S P Cullen; M Brunet; S J Martin
Journal:  Cell Death Differ       Date:  2010-01-15       Impact factor: 15.828

Review 9.  The senescence-associated secretory phenotype: the dark side of tumor suppression.

Authors:  Jean-Philippe Coppé; Pierre-Yves Desprez; Ana Krtolica; Judith Campisi
Journal:  Annu Rev Pathol       Date:  2010       Impact factor: 23.472

10.  Engineering of macrophages to produce IFN-gamma in response to hypoxia.

Authors:  L Carta; S Pastorino; G Melillo; M C Bosco; S Massazza; L Varesio
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

View more
  3 in total

1.  Tumour inflammatory response: adding fuel to the fire?

Authors:  M Valdes; M R Chasen
Journal:  Curr Oncol       Date:  2015-02       Impact factor: 3.677

Review 2.  Pregnane xenobiotic receptor in cancer pathogenesis and therapeutic response.

Authors:  Satyanarayana R Pondugula; Sridhar Mani
Journal:  Cancer Lett       Date:  2012-08-29       Impact factor: 8.679

Review 3.  Homeostatic chemokines guide lymphoma cells to tumor growth-promoting niches within secondary lymphoid organs.

Authors:  Uta E Höpken; Armin Rehm
Journal:  J Mol Med (Berl)       Date:  2012-05-11       Impact factor: 4.599

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.